Literature DB >> 28689244

Changes in Management of Poorly Compliant Bladder in Botulinum Toxin A Era.

Nachiketh Soodana Prakash1, Diana M Lopategui1, Christopher Gomez2.   

Abstract

Bladder compliance is a measure of distensibility. Maladies such as myelodysplasia, myelomeningocele, spinal cord injury, multiple sclerosis and obstructive uropathy are known to decrease bladder compliance. Decrease in bladder compliance is a characteristic of neurogenic bladders. The pathophysiology of bladder compliance is complex but ultimately leads to high pressure during filling and storage phases. These high pressures lead to renal impairment, incontinence, and recurrent urinary tract infections. This review presents management of poorly compliant bladders with onabotulinumtoxinA.

Entities:  

Keywords:  Bladder compliance; Botox; Hypocompliant bladder; OnabotulinumtoxinA; SCI

Mesh:

Substances:

Year:  2017        PMID: 28689244     DOI: 10.1007/s11934-017-0707-6

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  37 in total

Review 1.  Clinical comparability of marketed formulations of botulinum toxin.

Authors:  Cristina Sampaio; João Costa; Joaquim J Ferreira
Journal:  Mov Disord       Date:  2004-03       Impact factor: 10.338

Review 2.  Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review.

Authors:  Todd A Linsenmeyer
Journal:  J Spinal Cord Med       Date:  2013-09       Impact factor: 1.985

3.  Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity.

Authors:  A Conte; A Giannantoni; S Proietti; S Giovannozzi; G Fabbrini; A Rossi; M Porena; A Berardelli
Journal:  Eur J Neurol       Date:  2011-12-28       Impact factor: 6.089

4.  Focal changes in nerve, muscle and connective tissue in normal and unstable human bladder.

Authors:  R G Charlton; A R Morley; P Chambers; J I Gillespie
Journal:  BJU Int       Date:  1999-12       Impact factor: 5.588

5.  Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions.

Authors:  Jakkrit Klaphajone; Wasuwat Kitisomprayoonkul; Supon Sriplakit
Journal:  Arch Phys Med Rehabil       Date:  2005-11       Impact factor: 3.966

6.  Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.

Authors:  David Ginsberg; Angelo Gousse; Veronique Keppenne; Karl-Dietrich Sievert; Catherine Thompson; Wayne Lam; Mitchell F Brin; Brenda Jenkins; Cornelia Haag-Molkenteller
Journal:  J Urol       Date:  2012-04-12       Impact factor: 7.450

7.  Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.

Authors:  Brigitte Schurch; Marianne de Sèze; Pierre Denys; Emmanuel Chartier-Kastler; Francois Haab; Karel Everaert; Pierre Plante; Brigitte Perrouin-Verbe; Catherine Kumar; Stephanie Fraczek; Mitchell F Brin
Journal:  J Urol       Date:  2005-07       Impact factor: 7.450

8.  OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.

Authors:  Eric Rovner; Roger Dmochowski; Christopher Chapple; Catherine Thompson; Wayne Lam; Cornelia Haag-Molkenteller
Journal:  Neurourol Urodyn       Date:  2013-02-06       Impact factor: 2.696

9.  Alterations in the molecular determinants of bladder compliance at hydrostatic pressures less than 40 cm. H2O.

Authors:  Björn O Backhaus; Martin Kaefer; Karen M Haberstroh; Karen Hile; Jiro Nagatomi; Richard C Rink; Mark P Cain; Anthony Casale; Rena Bizios
Journal:  J Urol       Date:  2002-12       Impact factor: 7.450

10.  Management of Low Compliant Bladder in Spinal Cord Injured Patients.

Authors:  Won Hee Park
Journal:  Low Urin Tract Symptoms       Date:  2010-07-30       Impact factor: 1.592

View more
  5 in total

1.  Irreversible Bladder Remodeling Induced by Fibrosis.

Authors:  Su Jin Kim; Jayoung Kim; Yong Gil Na; Khae Hawn Kim
Journal:  Int Neurourol J       Date:  2021-05-31       Impact factor: 3.038

2.  Conservative management of hostile bladders with intravesical botulinum toxin for successful renal transplantation.

Authors:  Sida Niu; Paul Black; Priya Padmanabhan
Journal:  Urol Case Rep       Date:  2018-10-25

Review 3.  Diagnosis and treatment of urinary and sexual dysfunction in hereditary TTR amyloidosis.

Authors:  Imad Bentellis; Gérard Amarenco; Xavier Gamé; Dora Jericevic; Mehdi El-Akri; Caroline Voiry; Lucas Freton; Juliette Hascoet; Quentin Alimi; Jacques Kerdraon; Benjamin M Brucker; Benoit Peyronnet
Journal:  Clin Auton Res       Date:  2019-08-26       Impact factor: 4.435

Review 4.  Will repeated botulinum toxin A improve detrusor overactivity and bladder compliance in patients with chronic spinal cord injury?

Authors:  Sheng-Fu Chen; Hann-Chorng Kuo
Journal:  Tzu Chi Med J       Date:  2020-07-29

5.  Conservative management of bladder endometriosis with acute renal failure.

Authors:  Mark C Xu; Amanda C Yunker; Melissa R Kaufman
Journal:  Urol Case Rep       Date:  2020-05-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.